In a significant development for the Indian healthcare sector, the cardiac and anti-diabetes drugs market has expanded more than threefold over the past decade, according to recent data from market research firm Pharmarack.

根据市场研究公司Pharmarack的最新数据，印度医疗保健部门的一个重大发展是，心脏和抗糖尿病药物市场在过去十年中扩大了三倍以上。

The anti-diabetes segment has seen remarkable growth, escalating from ₹5,000 crore in 2014 to nearly ₹17,000 crore today. Similarly, the cardiac market has also experienced substantial expansion, rising from ₹10,000 crore to approximately ₹30,000 crore during the same period.

抗糖尿病领域取得了显著增长，从2014年的50亿欧元上升到今天的近17亿欧元。同样，心脏市场也经历了大幅扩张，同期从10万欧元增至约30万欧元。

Sheetal Sapale, Vice President of Commercial at Pharmarack, attributes this impressive growth to the introduction of innovative medicines, which, despite their premium pricing, have significantly enhanced market reach and value. “The surge in market size can be largely credited to the emergence of new, effective treatments that have captured the attention of healthcare providers and patients alike,” she explained..

Pharmarack商业副总裁Sheetal Sapale将这一令人印象深刻的增长归因于创新药物的引入，尽管它们的价格很高，但却大大提高了市场覆盖率和价值。她解释道：“市场规模的激增在很大程度上归功于新的有效治疗方法的出现，这些治疗方法引起了医疗保健提供者和患者的关注。”。。

The data reveals a noteworthy trend in the marketplace: there are currently four brands in India that boast a turnover of at least ₹200 crore, a stark contrast to a decade ago when none achieved such figures. In the anti-diabetes segment specifically, around 13 brands now report turnovers ranging from ₹200-400 crore, together contributing approximately 26% to the total diabetes market..

数据揭示了市场上一个值得注意的趋势：目前印度有四个品牌的营业额至少达到20亿欧元，与十年前没有一个品牌达到这样的数字形成鲜明对比。特别是在抗糖尿病领域，目前约有13个品牌的营业额在20-40亿欧元之间，合计约占糖尿病总市场的26%。。

This rapid expansion can be linked to the changing dynamics in the pharmaceutical industry. “If I look at the contribution of these segments to diabetes, it becomes a little mind-boggling,” Sapale remarked. “Thirteen brands contributing to almost 26% of the market is a testament to how significantly these brands have grown.”.

这种快速扩张可能与制药行业不断变化的动态有关。Sapale说：“如果我看看这些部分对糖尿病的贡献，就会有点令人难以置信。”。“13个品牌占据了近26%的市场份额，这证明了这些品牌的发展程度。”。

Another striking aspect of this growth is the increase in the number of brands within the diabetes segment, which has more than doubled since 2018. The count has risen from 653 to a much larger figure, indicating a burgeoning competitive landscape.

这种增长的另一个引人注目的方面是糖尿病细分市场中品牌数量的增加，自2018年以来，品牌数量增加了一倍多。这一数字从653上升到了一个更大的数字，表明竞争格局正在迅速发展。

Sapale explained that the increase in brand numbers is largely due to the loss of patents for several innovative molecules starting in 2019. As these patents expired, numerous branded generics entered the market, leading to a flood of new brands. “This doubling of the market number of brands has been facilitated by the influx of generics that emerged post-patent expiration,” she added..

Sapale解释说，品牌数量的增加主要是由于从2019年开始失去了几个创新分子的专利。随着这些专利的过期，许多品牌仿制药进入市场，导致大量新品牌涌入。她补充道：“专利到期后出现的仿制药的涌入促进了品牌市场数量的翻倍。”。。

She clarified that her analysis focused on brands with turnovers between ₹1-10 crore, but acknowledged that including brands with turnovers below ₹1 crore would reveal an even more extensive array of market participants.

她澄清说，她的分析侧重于营业额在1-1千万欧元之间的品牌，但她承认，将营业额低于1千万欧元的品牌包括在内，将揭示出更广泛的市场参与者。

In a conversation with Medgate Today, Sapale emphasized the transformative shift occurring within the cardiac and anti-diabetes drug markets.She expressed optimism about the future of these segments, noting the potential for continued innovation and growth.

在今天与Medgate的对话中，Sapale强调了心脏和抗糖尿病药物市场发生的变革性转变。她对这些细分市场的未来表示乐观，并指出了持续创新和增长的潜力。

With a diverse range of brands and a focus on advanced treatments, the cardiac and anti-diabetes drug markets in India are not only expanding but are also becoming increasingly competitive. This growth represents a vital opportunity for stakeholders in the healthcare industry to engage with emerging trends and contribute to better health outcomes across the region..

印度的心脏和抗糖尿病药物市场不仅在扩大，而且竞争也越来越激烈，品牌多样，专注于先进的治疗方法。这一增长为医疗保健行业的利益相关者提供了一个重要的机会，可以参与新兴趋势，并为整个地区更好的健康结果做出贡献。。